• Skip to primary navigation
  • Skip to main content
  • Skip to footer
HCM Studies

HCM Studies

  • About HCM
    • Overview
    • Causes
    • Symptoms
    • Diagnosis
  • Gene Therapy for HCM
    • Basic Genetics
    • Mutations & Disease
    • Gene Therapy
    • AAV Capsids
    • TN-201 for HCM
  • Our Studies
    • MyPeak-1
    • MyClimb
  • Resources

Participate in Research for Hypertrophic Cardiomyopathy (HCM)

Learn about clinical trials looking at a potential therapy to address mutations in the MYBPC3 gene, the leading genetic cause of HCM.

Learn More

A Phase 1b clinical trial of an investigational gene therapy called TN-201 for the treatment of HCM caused by mutations in the MYBPC3 gene.

Learn More

A natural history study designed to collect and evaluate information on how cardiomyopathy changes over time in infants, children, and teens with the MYBPC3 gene mutation. This study only involves review of your medical records and blood draw.

Learn More

About Hypertrophic Cardiomyopathy (HCM)

HCM is a condition that increases the thickness of the heart muscle, which can limit the heart’s ability to function effectively.

Learn More

Gene Therapy for
HCM

By delivering a working gene to heart muscle cells, gene therapy has the potential to correct the underlying cause of genetic heart conditions, like HCM.

Learn More

Contact Us

Email the patient advocacy team at Tenaya for more information about taking part in research for MYBPC3-associated HCM.

Footer

  • X formerly twitter
  • LinkedIn
  • Facebook
  • Instagram

This website is a service of Tenaya Therapeutics, Inc., a clinical-stage biotechnology company committed to a bold mission: to discover, design, develop and deliver potentially curative therapies that address the underlying causes of heart disease.

  • Expanded Access Policy
  • Privacy Policy
  • Cookie Policy
  • Terms & Conditions
  • Community Guidelines

© 2024 Tenaya Therapeutics. All rights reserved
Last Updated July 1, 2024